WALTHAM, Mass--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, has been featured in several media outlets and in patient interviews.
The Company operates in two primary markets – wearable medical technology and point-of-care tests. The Company’s SENSUS™ device is a wearable transcutaneous electrical nerve stimulator indicated for management of chronic pain, and is the only such device cleared by the FDA for use during sleep. It is lightweight and can be worn during the day while remaining active, and at night while sleeping. SENSUS is beneficial in treating various forms of chronic pain, particularly neuropathic pain such as painful diabetic neuropathy, which affects about one quarter of people with diabetes. The Company’s point-of-care neuropathy test, DPNCheck®, addresses an unmet medical need for accurate and cost-effective screening, diagnosing and monitoring of peripheral neuropathies such as diabetic peripheral neuropathy. DPNCheck has found growing acceptance among Medicare Advantage plans where it is used in the clinically and financially important risk adjustment process.
Shai Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix participated in a live interview and Q&A session with TuDiabetes.org, a diabetic community and a program of the Diabetes Hands Foundation. The discussion covered a wide range of diabetes and neuropathy topics and included discussion of SENSUS and DPNCheck. To listen to the interview, please visit the following link: http://youtu.be/JPJ7BSA66Hk
In an article by Dr. Vincent R. Forte, Interventional Pain Management Specialist at Louisiana Pain Care, on the topic of “Managing Painful Diabetic Neuropathy”, Dr. Forte described SENSUS as a simple, convenient therapy that has provided encouraging results in clinical settings. He emphasized the “on-demand” aspect of SENSUS and its effectiveness during sleep. The article was published in the March poster of Physicians Weekly which is distributed to 1,500 U.S. hospitals and clinics. To see the poster, please visit the following link: http://www.physiciansweekly.com/diabetic-neuropathy-pain-management/
DiaTribe which covers research and product news for people with diabetes published “Diabetic Neuropathy - Knowledge is Power” by Alasdair Wilkins. The article describes diabetic neuropathy, the warning signs, prevention, and treatment options. It mentions medications to help manage the pain that can accompany neuropathy and it covers the SENSUS Pain Management System. To read the article, please visit the following link: http://www.diatribe.org/issues/61/learning-curve/2?utm_source=diaTribe&utm_campaign=8dc6a2ec8b-diaTribe_Issue_59&utm_medium=email&utm_term=0_75cdadd67f-8dc6a2ec8b-410724717
The spring edition of Better Homes and Gardens - Diabetes Edition includes an article “Stand Up To Leg Pain” which discusses diabetic neuropathy and highlights SENSUS as an FDA approved TENS device that can be worn under clothes during the day and at night to address neuropathic pain. To read the article, please visit the following link: http://www.sensusrx.com/about-neurometrix/news-and-events/better_homes_&_gardens_-_diabetic_living_spring_2014_final.pdf
Recent interviews with patients using SENSUS have highlighted its benefits. Patients emphasize its role in allowing them to return to a more active lifestyle. A recurring theme is the ability to improve sleep duration and quality, and the attendant benefits in quality of life. Convenience of use is often mentioned. To hear these and other patient commentary on SENSUS, please visit the NeuroMetrix website at the following link: http://www.sensusrx.com/learn-about-sensus/user-experiences.html
NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The Company has a major focus on diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The Company markets the SENSUS device for treating chronic pain, focusing on physicians managing patients with neuropathic pain such as painful diabetic neuropathy. The Company also markets DPNCheck, which is a rapid, accurate, and quantitative point-of-care test for peripheral neuropathies such as diabetic neuropathy. This product is used to detect neuropathies at an early stage and to guide treatment. For more information, please visit http://www.NeuroMetrix.com.